Table 1. Baseline demographic and epidemiological characteristics of trial participants.
Figures are numbers of participants (percentage) unless stated otherwise.
| Parameter | Overall N = 154 | Low dose N = 76 | High dose N = 78 | |
|---|---|---|---|---|
| Study Center | Damak | 55 (35·7%) | 27 (35·5%) | 28 (35·9%) |
| Charali | 26 (16·9%) | 12 (15·8%) | 14 (18·0%) | |
| Bharatpur | 73 (47·4%) | 37 (48·7%) | 36 (46·2%) | |
| Sex | Female | 80 (51·9%) | 39 (51·3%) | 41 (52·6%) |
| Male | 74 (48·1%) | 37 (48·7%) | 37 (47·4%) | |
| Age (years) | Median (IQR) | 28 (16–46) | 26 (16–44) | 32 (17–49) |
| Time to reach center (min) | Median (IQR) | 75 (45–148) | 66 (41–134) | 80 (50–150) |
| Missing | 7 | 2 | 5 | |
| Neurotoxic score on admission | Mean ± sd | 2·14 ± 1·18 | 2·21 ± 1·33 | 2·08 ± 1·01 |
| Snake species | Unidentified | 101 (65·6%) | ||
| Identified | 53 (34·4%) | |||
| Cobra | 31 (58%) | 15 (58%) | 16 (59%) | |
| Krait | 22 (42%) | 11 (42%) | 11 (41%) |